The Corner Series Podcast | Investor Interest: What’s Happening in Home Healthcare?

Barry Freeman, Managing Director in Lincoln’s Healthcare Group, joins Geoff Cockrell, host of the The Corner Series podcast, to discuss trends and investing opportunities in home health, hospice and palliative care. Barry shares his in-depth knowledge of the home healthcare space, including key takeaways from the recent Home Care 100 industry event. Barry also walks listeners through changes in the industry, where he believes the sector is headed and the advances being made to help manage risk.

Complete the form below to listen to the podcast



Summary

  • On March 4, 2022, Barry Freeman, Managing Director, joined McGuireWoods' The Corner Series | The Banker's Corner podcast to discuss trends and investing opportunities in home health, hospice and palliative care.

  • Sign up to receive Lincoln's perspectives

Contributor

Meet Professionals with Complementary Expertise

Related Perspectives

PETS International | Consolidation Meets Regulation in the Veterinary Clinics Market

Originally posted by PETS International on April 5, 2024. Animal health is becoming a big business in Europe and the U.S. Thus, regulators are turning a closer eye to mergers… Read More

“Leader to Leader” Series

The Leader to Leader video series turns up the dial on rich conversations with prominent leaders – from business owners and entrepreneurs to investors and CEOs – highlighting their stories… Read More

What Price is Right? Trends and Opportunities for Private Equity in Pharma Market Access

The cost of developing new drugs is staggering. Among the top 20 global biopharmas, the average cost of developing a candidate from discovery through clinical trials to market was approximately… Read More

Investment Opportunities in Pharma: A Data-Driven Exploration of CDMO Appeal

The report discusses the current state of the contract development and manufacturing organization (CDMO) market within the pharmaceutical industry, emphasizing the increased interest from private equity (PE) investors. The pharmaceutical… Read More